Mantle cell lymphoma (MCL) is an aggressive variant of B-cell non-Hodgkin lymphoma that comprises approximately 5% of all lymphomas. Compared with patients who have other aggressive lymphomas, patients with MCL often do not respond as well to treatment (ACS, 2019).Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 4 and 5 years (LLS, 2021). Though there are several effective options, there is no currently accepted standard of care for frontline treatment of MCL (Hanel & Epperla, 2020). Selecting treatments for relapsed/refractory disease is complicated by multiple factors individual to the patient (Cortelazzo et al 2020). In order to select optimal treatments for MCL, it is vital that clinicians be familiar with the latest research. In this activity, John P. Leonard, MD, will discuss the latest research into prognostic markers of MCL, the efficacy and safety of novel therapeutic strategies, and approaches to optimize tolerability of treatments.